Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Proposal For Increased Sunscreen Safety Testing On NDAC Agenda

This article was originally published in The Tan Sheet

Executive Summary

FDA’s Nonprescription Drug Advisory Committee will consider proposed tests for evaluating the safety of sunscreen ingredients that sponsors want to add to the OTC monograph. The committee will not consider the safety or efficacy of specific ingredients pending review via TEAs.

Advertisement

Related Content

NDAC Input Sought On Sunscreen Ingredient Data Necessary For Approval
FDA Faults BASF Sunscreen Ingredient Data In Latest TEA Rejection
FDA Says Antiseptics Need Testing Or Face Reformulation, Relabeling
Sunscreen Group Suggests User Fees To Expedite Ingredient Reviews

Topics

Advertisement
UsernamePublicRestriction

Register

PS107111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel